At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2)
In Brief
A Phase 4 clinical trial evaluating Resolute Integrity (Zotarolimus-eluting stent) and Promus Element (Everolimus-eluting stent) for Acute Coronary Syndrome and 6 related conditions. Completed, enrolled 1,811 participants across 4 sites.
Detailed Summary
The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity but there are further demands on DES performance. Such demands are an optimized performance in very challenging coronary lesions; third generation DES were developed in an effort to further improve DES performance in such challenging lesions. Two CE-certified third generation DES (Resolute Integrity and Promus Element stents) are currently available; there are no data that indicate an advantage of one of these DES over the other.
Study Details
Timeline
Interventions
Third generation drug-eluting stent
Third generation drug-eluting stent